Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Sep 19 2011

• By Emily Hayes

Related Content

Financings Of The Fortnight: Market Lessons From The Contrave Complete Response Letter

Feb 04 2011

<i>Halaven</i> Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval

May 01 2011

Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain

Nov 16 2010

Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself

Dec 13 2010

Quality-Of-Life Data Take On Added Significance With <i>Avastin</i> Debate

Jul 18 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window